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Edited by Robert BaroukiAbstract To investigate the role of lipopolysaccharide (LPS) in
hepatocyte activation, we examined the expression of Toll-like
receptor 4 (TLR4), the putative receptor for LPS in human
hepatocytes. TLR4 mRNA and protein expression was con-
ﬁrmed in human hepatocytes. Stimulation of human hepatocytes
with LPS results in rapid degradation of IkappaB-a and mitogen
activated protein kinase activation. Human hepatocytes stimu-
lated by LPS produced serum amyloid A protein. Our data
suggest that human hepatocytes utilize components of TLR4
signal transduction pathways in response to LPS and these direct
LPS-mediated eﬀects on hepatocytes may contribute to liver
inﬂammation and injury.
 2004 Federation of European Biochemical Societies. Published
by Elsevier B.V. All rights reserved.
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Bacterial lipopolysaccharide (LPS), an essential component
of the outer membrane of gram-negative bacteria, provokes a
generalized proinﬂammatory response in the infected host that
leads to septic shock and multiple organ failure [1]. LPS also
causes liver injury [2]. The liver is an immunocompetent organ
that plays a key role in the innate immune responses to
pathogens [3]. The liver produces both inﬂammatory media-
tors and acute-phase reactants and functions to remove
pathogens and microbial products from the blood [4]. Al-
though hepatocytes have been reported to respond to LPS, the
mechanisms by which LPS stimulates human hepatocytes re-
main uncertain. It has been suggested that Kupﬀer cells, as well
as other macrophage populations, are responsive to LPS and
produce TNF-a and IL-1 that activate hepatocytes [5]. Re-
cently, Toll-like receptors (TLRs), several mammalian Toll
homologues, have been identiﬁed and shown to play important* Corresponding author. Fax: +81-957-54-0292.
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humans, the TLR family consists of 10 members, all of which
are involved in the recognition of pathogen-associated mo-
lecular patterns [7]. Among these, Toll-like receptor 4 (TLR4)
has been shown to be critical for LPS and endotoxin signaling
[8]. TLR receptors have been identiﬁed on monocytes, mac-
rophages, Kupﬀer cells and dendritic cells, and LPS binds to
Kupﬀer cells via TLR4 [9]. LPS activation of Kupﬀer cells
leads to upregulation of inﬂammatory cytokines, which are
involved in liver damage [10]. Therefore, the general view is
that the Kupﬀer cell is the major target of LPS in the liver.
Serum amyloid A protein (SAA) is a major acute-phase pro-
tein (APP) produced in the liver after various insults such as
infection and inﬂammation [11]. SAA is an apolipoprotein that
belongs to class 1 APP in which IL-1 and IL-6 are the main in-
ﬂammatory mediators involved in its transcriptional induction
[12]. Multiple cis-acting elements, including C/EBP andNF-jB,
have been found to be important for SAA genes [13]. LPS in-
jection in rabbit results in the activation of C/EBP and NF-jB,
which may be responsible for LPS-induced SAA induction [14].
NF-jB and NF-IL6 are involved in the cytokine-induced SAA
gene expression [15]. SAF-1 is a zinc ﬁnger transcription factor
that is essential for cytokine-induced SAA induction [16]. It was
demonstrated that MAPK signaling pathway regulated the
DNA-binding activity and transactivation potential of SAF-1
and phosphorylation of SAF-1 in response to cytokines was
markedly inhibited by MAPK inhibitors [17]. More recently, it
was demonstrated that LPS-stimulated SAA protein induction
was signiﬁcantly reduced in TLR4-deiﬁcient mice, suggesting
the critical role of TLR4 in SSA induction [18]. In the present
study, to determine whether hepatocytes respond directly to
LPS and produce SAA, we investigated the presence of TLR4, a
ligand of LPS, in human hepatocytes.2. Materials and methods
2.1. Cells
Human primary hepatocytes were purchased from Cell Systems
(Kirkland, WA). The cells were cultured in a basal medium composed
of Ham’s F-12 and Leibovitz L-15 (1:1) medium (Invitrogen, Carlsbad,
CA), 0.2% (v/v) bovine serum albumin, 5 mM glucose (Wako Chem-
ical Co Inc., Osaka, Japan), 108 M dexamethasone (Wako), and 108
M bovine insulin (Invitrogen) supplemented with 10% (v/v) fetal calf
serum (FCS, Gibco, Grand Island, NY). These hepatocytes prepara-blished by Elsevier B.V. All rights reserved.
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bodies (eBioscience, San Diego, CA), indicating that these cells were
free of monocyte/macrophage.
2.2. Flow cytometry for determination of TLR4 expression
Adherent human hepatocytes were detached using 1 mM EDTA.
Cell surface staining was performed using anti-human TLR4 phyco-
erythrin (eBioscience, San Diego, CA). Isotype-matched non-bonding
control antibodies were used for comparison. Cells were analyzed us-
ing a EPCS XL (Coulter, Fullerton, CA). A total of 10 000 immuno-
ﬂuorescent events were acquired for each sample.
2.3. Immunoblot analysis
Whole cell lysates were prepared from LPS-stimulated hepatocytes
using Triton lysis buﬀer containing protease and phosphatase inhibitor
(1% Nonidet-P 40, 50 mM Tris, pH 7.5, 100 mMNaCl, 50 mM NaF, 5
mM EDTA, 20 mM b-glycerophosphate, 1.0 mM sodium ortho-
vanadate, 10 lg/mL aprotinin and 10 lg/mL leupeptin). One hundred
micrograms of protein was electrophoresed on 10% SDS polyacryl-
amide gels. The fractionated proteins were transferred to nitrocellulose
membranes and probed by anti-IkappaB-a (IjB-a), phospho-extra-
cellular signal-related kinase (ERK)1/2, phospho-p38 and phospho-
JNK1/2 antibodies (1:1000 dilution, Biosource, Camarillo, CA).
Hepatocytes culture supernatants were also electrophoresed on 14%
polyacrylamide gels. The fractionated proteins were transferred to a
nitrocellulose membrane (pore-size: 0.2 l, Bio-Rad, Hercules, CA) and
probed with rabbit anti-SAA antibodies (1:2000 dilution) and devel-
oped using an enhanced chemiluminesence (ECL) system (Amersham,
Arlington Heights, IL).Fig. 1. Expression of TLR4 and MyD88 mRNA in human hepato-
cytes. (A) Total RNA was obtained from THP-1 cells (lanes 1 and 3)
and human hepatocytes and TLR4 and MyD88 mRNA were analyzed
by PCR following reverse transcription. (B) b-Actin expression in
THP-1 cells (lane 1) and human hepatocytes (lane 2) were used as
control.2.4. RNA preparation and RT-PCR assay
Total cellular RNA was extracted from hepatocytes using guanidium
thiocyanate and phenol (RNAzol B, Cinna/Biotek Labs Int. Inc.,
Friendswood, TX). First-strand cDNA was synthesized by reverse
transcription at 45 C for 45 min in a 50 ll reaction mixture containing
1 lg of total RNA and MuLV reverse transcriptase (Invitrogen). After
denaturing at 99 C for 5 min followed by cooling at 5 C, the cDNA
was ampliﬁed using PCR. Two microliters of denatured cDNA was
ampliﬁed in a 20 ll ﬁnal volume containing 1 U Taq DNA polymerase
(Gibco-BRL, Gaithersburg, MD), 1 lM of each primer, Taq poly-
merase buﬀer, 1.5 mM MgCl2 and 1.5 mM of each dNTP. PCR was
performed in a thermal cycler (Perkin–Elmer–Cetus, Foster City, CA)
using a program of 30 cycles of 95 C for 1 min, 55 C for 1 min, and 72
C for 1 min with a ﬁnal 10 min extension at 72 C. The ampliﬁed
products were subjected to electrophoresis on 2% agarose gel.
The speciﬁc primers used for TLR4 were
50-TTGTATTCAAGGTCTGGCTGG-30 (forward),
50-GCAACCTTTGAAACTCAAGCC-30 (reverse).
The predicted size of the fragment was 436 bp.
For MyD88:
50-CCGCGCTGGCGGAGGAGATGGAC-30 (forward),
50-GCAGATGAAGGCATCGAAACGCTC-30 (reverse).
The predicted size of the fragment was 356 bp.
For b-actin:
50-GACGAGGCCCAGAGCAAGAGAG-30 (forward),
50-ACGTACATGGCTGGGGTGTTG-30 (reverse).
The predicted size of the fragment was 236 bp.
For SAA1:
50-CAGACAAATACTTCCATGCT-30 (forward),
50-ATTGTGTACCCTCTCCCCC-30 (reverse).
The predicted size of the fragment was 303 bp.
For SAA2:
50-CAGACAAATACTTCCATGCT-30 (forward),
50-ATTATATGCCATATCTCAGC-30 (reverse).
The predicted size of the fragment was 328 bp.Fig. 2. Eﬀects of cytokines on TLR4 expression on human hepatocytes.
Human hepatocytes were treated with media, LPS (100 ng/ml), TNF-a
(100 ng/ml) or IFN-c(100 ng/ml) for 24 h. Expression of TLR4 on
hepatocytes was measured by ﬂowcytometer and represented as
changes in ﬂuorescence between TLR4 and the isotype control. Dotted
line: isotype-matched control Ab. Solid line: TLR4 expression on he-
patocytes. Values in upper right of graph represent mean ﬂuorescence
intensity of TRL4 expression. The data shown are representatives of at
least three independent experiments.3. Results
3.1. Expression of TLR4 in human hepatocytes
We ﬁrst examined the mRNA expression of the LPS
receptor molecule TLR4 and an intracellular adaptor protein
for TLR4, MyD88, in human hepatocytes. Total RNA wasextracted from hepatocytes and THP-1 cells, a monocyte cell
line. The expression of TLR4 and MyD88 genes was analyzed
by reverse-transcription PCR. As shown in Fig. 1, TLR4 and
MyD88 mRNA were detected in human hepatocytes. THP-1
cells, which express TLR4 and MyD88 mRNA, served as a
positive control. To assess the protein expression of TLR4 in
human hepatocytes, we undertook immunoﬂuorescence
staining for the presence of TLR4 in human hepatocytes using
ﬂow cytometry. As shown in Fig. 2, signiﬁcant fractions of
human hepatocytes constitutively expressed TLR4. To inves-
Fig. 4. LPS stimulation induces MAPK activation in hepatocytes.
Quiescent human hepatocytes were stimulated with LPS (100 ng/ml)
for 15 min. Cells were lysed and cellular lysates were analyzed by
immunoblot using anti-phospho-speciﬁc ERK1/2 (A), p38 (B) and
JNK1/2 (C) antibodies. The data shown are representatives of at least
three independent experiments.
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ﬂammatory stimuli, we examined the eﬀects of LPS, TNF-a
and IFN-c on TLR4 expression in hepatocytes. Human he-
patocytes were stimulated with E. coli LPS (100 ng/ml), TNF-a
(50 ng/ml) or IFN-c (100 ng/ml) for 24 h, and the expression of
TLR4 was analyzed by ﬂow cytometry. TLR4 expression on
hepatocytes was not modulated by these stimuli (Fig. 2).
3.2. LPS stimulates IjB-a degradation and MAPK activation
To determine whether LPS stimulation transmits a signal
across the cell membrane in hepatocytes, we investigated the
eﬀects of LPS on the NF-jB and MAPK. Phosphorylation and
subsequent degradation of IjB-a, an inhibitor of NF-jB, re-
sult in the activation of NF-jB [19]. To conﬁrm LPS-induced
NF-jB activation, we evaluated the IjB-a proteolysis. The
protein levels of IjB-a in LPS-treated hepatocytes were mea-
sured by immunoblot analysis. LPS stimulation induced sub-
stantial IjB-a degradation in a time-dependent manner,
suggesting the activation of NF-jB in hepatocytes (Fig. 3).
LPS-mediated TLR4 signaling has also been found to trigger
the activation of MAPKs. As shown in Fig. 4A, LPS had in-
duced the phosphorylation of ERK1/2 at 15 min after stimu-
lation. Similarly, LPS stimulation resulted in the
phosphorylation of p38 (Fig. 4B) and JNK1/2 (Fig. 4C) in
human hepatocytes. These results indicate that LPS activates
MAPK signaling in human hepatocytes.
3.3. LPS induces SAA secretion from human hepatocytes
To investigate whether the TLR4 expressed on human he-
patocytes is functional, the eﬀects of LPS, a natural ligand for
TLR4, on human hepatocytes were analyzed. We examined the
secretion of SAA, a speciﬁc protein produced by hepatocytes.
Human hepatocytes were incubated with varying doses of LPS
in the presence or absence of 10% FCS for 24 h, and culture
supernatants were removed and analyzed by anti-SAA im-
munoblot. Fig. 5A shows the secretion of SAA from LPS-
stimulated human hepatocytes in a dose-dependent manner.
LPS did not induce SAA production from human hepatocytes
in the absence of serum (Fig. 5C). This result indicates that
LPS-induced SAA production in hepatocytes was dependent
on the presence of serum, a source of the LPS-binding protein
(LBP) that is required for LPS to act through TLR4. Poly-
myxin B is an antibiotic that binds the lipid A motif of LPS
and inactivates its biological function [20]. Preincubation with
polymyxin B (100 IU/ml) before stimulation completely in-
hibited LPS-induced SAA production from human hepato-
cytes (Fig. 5B). To assess the functional role of TLR4,
hepatocytes were incubated with anti-TLR4 monoclonal an-Fig. 3. LPS stimulated IjB-a degradation in hepatocytes. Human he-
patocytes were stimulated with LPS (100 ng/ml) for the indicated
times. Cells were lysed and cellular lysates were assessed by anti-IjB-a
immunoblot analysis. The data shown are representatives of at least
three independent experiments.tibodies (HAT 125, eBioscience) for 6 h before stimulation
with LPS. Hepatocytes preincubated with anti-TLR4 resulted
in a reduced SAA synthesis, demonstrating that LPS utilizes
TLR4 in human hepatocytes (Fig. 5D).
To conﬁrm the LPS-stimulated induction of SAA at mRNA
levels, we determined the levels of acute-phase SAA (SAA1,
SAA2) in LPS-stimulated human hepatocytes using RT-PCR
methods. Although the expression levels of SAA1,2 mRNA in
unstimulated hepatocytes were below the limit of detection,
signiﬁcant levels of SAA1,2 mRNA expression were detected
after 3 h of LPS stimulation (Fig. 6). In contrast, b-actin
mRNA was constitutively expressed in hepatocytes and un-
changed by LPS stimulation.4. Discussion
Lipopolysaccharide (LPS) derived from gut bacteria has
been implicated in this liver injury [21]. It has been suggested
that LPS exerts an indirect eﬀect on hepatocytes and that
Fig. 5. (A) LPS induces SAA synthesis from human hepatocytes. Human hepatocytes were stimulated with the indicated concentrations of LPS for 24
h. SAA production was measured by anti-SAA immunoblot using culture supernatants. The data shown are representatives of at least three in-
dependent experiments. (B) LPS-induced SAA production is inhibited by Polymyxin B. Human hepatocytes were stimulated by LPS (100 ng/ml) for
24 h with or without pretreatment of polymyxin B for 30 min. SAA production was measured by anti-SAA immunoblot using culture supernatants.
Lane 1: untreated; lane 2: treated with LPS (100 ng/ml); lane 3: treated with Polymyxin B (2 IU/ml) plus LPS; lane 4: treated with Polymyxin B (10
IU/ml) plus LPS. The data shown are representative of at least two independent experiments. (C) LPS-induced SAA synthesis depends on the
presence of serum. Human hepatocytes were stimulated with LPS (100 ng/ml) in the presence or absence of 10% FCS for 24 h. SAA production was
measured by anti-SAA immunoblot using culture supernatants. The data shown are representative of at least two independent experiments. (D)
Eﬀects of mAbs on TLR4 on the production of SAA by hepatocytes stimulated with LPS. Before the stimulation with LPS, human hepatocytes were
pretreated with anti-TLR4 mAbs. SAA production was measured by anti-SAA immunoblot using culture supernatants. The data shown are rep-
resentatives of at least two independent experiments.
Fig. 6. LPS induces SAA1,2 mRNA expression in human hepatocytes.
Human hepatocytes were stimulated with LPS (100 ng/ml) for the
indicated times. Expression on SAA1 (A) and SAA 2 (B) was analyzed
by PCR following reverse transcription. b-Actin expression was used
as control. The data shown are representatives of at least two inde-
pendent experiments.
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studies have raised the possibility that hepatocytes respond
directly to LPS. Recently, it was demonstrated that murine
hepatocytes express TLRs and respond to LPS through the
TRL4 receptor pathway [23]. In this study, we demonstrated
the mRNA expression of TLR4 and MyD88, a co-receptor for
LPS, in human hepatocytes. Furthermore, hepatocytes ex-
pressed TLR4 on the cell surface at the protein level. These
data indicate that human hepatocytes express LPS recognition
molecules and suggest the possibility that hepatocytes respond
to LPS directly.
Monocyte/macrophage exposed to LPS show the reduced
surface TLR4 expression, which is thought to be one of the
mechanisms of LPS tolerance [24]. In our data, TLR4 ex-
pression on hepatocytes was not modulated by LPS stimula-tion. Although the mechanism for the TLR4 downregulation
in LPS-tolerant macrophages has not been clariﬁed, these
discrepancies in responses to LPS could be due to the diﬀer-
ential cell types.
We then focused on the LPS signal transduction cascade in
human hepatocytes. Upon binding of LPS to TLR4, MyD88,
an adaptor protein, links TLR4 to IL-1R-associated protein
kinase (IRAK) and IRAK is phosphorylated [25]. Phosphor-
ylated IRAK dissociates from the receptor complex and acti-
vates tumor necrosis factor receptor-associated factor 6
(TRAF-6) [26]. Subsequently, TRAF-6 activates MAPKs and
NF-jB to produce cytokines and chemokines [27]. To assess
LPS signaling, we investigated whether LPS stimulation results
in the activation of these kinases or transcription factors in
human hepatocytes. MAPK are a group of serine/threonine
protein kinases that participate in transmitting extracellular
signals to the cell nucleus. LPS-induced MAPK activation was
previously demonstrated in murine hepatocytes [23]. Consis-
tent with these ﬁndings, our data indicate that LPS stimulation
resulted in the activation of ERK1/2, p38 and c-Jun N-termi-
nal kinase (JNK1/2). NF-jB is also shown to be activated by
LPS stimulation. NF-jB is sequestered in an active form in the
cytoplasm bound to inhibitor IjB-a. Extracellular stimuli in-
duce IjB kinase (IKK), which degrades IjB [19]. After deg-
radation of IjB, the NF-jB complex moves to the nucleus and
activates NF-jB-dependent transcription [19]. The ﬁnding that
LPS leads to the rapid degradation of IjB-a suggests that LPS
stimulation induces IKK activation in human hepatocytes.
Hepatocytes support intra- as well as extrahepatic defense
reactions by synthesis of APPs in inﬂammatory processes in-
cluding endotoxemia. SAA, one of the APPs, is produced by
hepatocytes in response to inﬂammatory cytokines such as
TNF-a, IL-1b and IL-6 [11,28]. We evaluated the eﬀects of
LPS on SAA synthesis in hepatocytes. Our results clearly in-
dicate that LPS directly induced SAA mRNA and protein
expression in human hepatocytes. This LPS-induced SAA
K. Migita et al. / FEBS Letters 569 (2004) 235–239 239synthesis was blocked by polymyxin B, a polypeptide antibi-
otic that inactivates the biological functions of LPS by re-
moving FCS, a source of LPS-binding protein that is required
for the interaction between LPS and TLR4 [29]. Recent reports
indicated that NF-jB and SAA activating factor (SAF) are
essential transcription factors for SAA gene expression
[30] and that activation of SAF is mediated by MAPKs [17].
LPS-mediated NF-jB and MAPK activation coordinate the
induction of SAA mRNA. SAA can induce chemotaxis of
neutrophils [31] and matrix metalloproteinases (MMPs) in-
duction [32], key processes involved in inﬂammation and tissue
destructions. It is possible that human hepatocytes respond to
LPS and participate in hepatic inﬂammation by producing
SAA during LPS-induced liver injury.
In conclusion, our data suggest that human hepatocytes are
capable of responding to a microbial product, LPS, directly
without the mediation of Kupﬀer cells and macrophages. This
LPS-mediated hepatocyte activation could be implicated in the
pathogenesis of endotoxin-induced liver injury.
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